FDA advisory group rejects Pacira’s pitch for expanded use of pain drug
A group of experts organized by the FDA has voted 6 to 4 against a move by Pacira Pharmaceuticals to get an approval to use its pain drug Exparel as a regional pain blocker, expanding on its approved use as a local anesthetic. And now the biotech may have to mount some new studies if it plans to pursue this much further.
In a novel use of language, the company noted in a statement that the advisory group “did not reach a unanimous decision on the efficacy and safety of the use of Exparel.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
